166 related articles for article (PubMed ID: 25277178)
1. Nuclear Eg5 (kinesin spindle protein) expression predicts docetaxel response and prostate cancer aggressiveness.
Wissing MD; De Morrée ES; Dezentjé VO; Buijs JT; De Krijger RR; Smit VT; Van Weerden WM; Gelderblom H; van der Pluijm G
Oncotarget; 2014 Sep; 5(17):7357-67. PubMed ID: 25277178
[TBL] [Abstract][Full Text] [Related]
2. A potent chemotherapeutic strategy in prostate cancer: S-(methoxytrityl)-L-cysteine, a novel Eg5 inhibitor.
Xing ND; Ding ST; Saito R; Nishizawa K; Kobayashi T; Inoue T; Oishi S; Fujii N; Lv JJ; Ogawa O; Nishiyama H
Asian J Androl; 2011 Mar; 13(2):236-41. PubMed ID: 21297652
[TBL] [Abstract][Full Text] [Related]
3. Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy.
Ploussard G; Terry S; Maillé P; Allory Y; Sirab N; Kheuang L; Soyeux P; Nicolaiew N; Coppolani E; Paule B; Salomon L; Culine S; Buttyan R; Vacherot F; de la Taille A
Cancer Res; 2010 Nov; 70(22):9253-64. PubMed ID: 21045157
[TBL] [Abstract][Full Text] [Related]
4. Docetaxel-resistant prostate cancer cells remain sensitive to S-trityl-L-cysteine-mediated Eg5 inhibition.
Wiltshire C; Singh BL; Stockley J; Fleming J; Doyle B; Barnetson R; Robson CN; Kozielski F; Leung HY
Mol Cancer Ther; 2010 Jun; 9(6):1730-9. PubMed ID: 20515952
[TBL] [Abstract][Full Text] [Related]
5. The significance of TNFAIP8 in prostate cancer response to radiation and docetaxel and disease recurrence.
Zhang C; Kallakury BV; Ross JS; Mewani RR; Sheehan CE; Sakabe I; Luta G; Kumar D; Yadavalli S; Starr J; Sreenath TL; Srivastava S; Pollard HB; Eidelman O; Srivastava M; Kasid UN
Int J Cancer; 2013 Jul; 133(1):31-42. PubMed ID: 23280553
[TBL] [Abstract][Full Text] [Related]
6. Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity.
Domingo-Domenech J; Oliva C; Rovira A; Codony-Servat J; Bosch M; Filella X; Montagut C; Tapia M; Campás C; Dang L; Rolfe M; Ross JS; Gascon P; Albanell J; Mellado B
Clin Cancer Res; 2006 Sep; 12(18):5578-86. PubMed ID: 17000695
[TBL] [Abstract][Full Text] [Related]
7. Initial biopsy Gleason score as a predictive marker for survival benefit in patients with castration-resistant prostate cancer treated with docetaxel: data from the TAX327 study.
van Soest RJ; de Morrée ES; Shen L; Tannock IF; Eisenberger MA; de Wit R
Eur Urol; 2014 Aug; 66(2):330-6. PubMed ID: 23957945
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant docetaxel treatment for locally advanced prostate cancer: a clinicopathologic study.
Magi-Galluzzi C; Zhou M; Reuther AM; Dreicer R; Klein EA
Cancer; 2007 Sep; 110(6):1248-54. PubMed ID: 17674353
[TBL] [Abstract][Full Text] [Related]
9. Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer.
Lin HM; Castillo L; Mahon KL; Chiam K; Lee BY; Nguyen Q; Boyer MJ; Stockler MR; Pavlakis N; Marx G; Mallesara G; Gurney H; Clark SJ; Swarbrick A; Daly RJ; Horvath LG
Br J Cancer; 2014 May; 110(10):2462-71. PubMed ID: 24714754
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of SLC6A1 associates with drug resistance and poor prognosis in prostate cancer.
Chen C; Cai Z; Zhuo Y; Xi M; Lin Z; Jiang F; Liu Z; Wan Y; Zheng Y; Li J; Zhou X; Zhu J; Zhong W
BMC Cancer; 2020 Apr; 20(1):289. PubMed ID: 32252682
[TBL] [Abstract][Full Text] [Related]
11. Case report: responses to cabazitaxel in metastatic castration-resistant prostate cancer after extensive docetaxel treatment.
Guancial EA; Taplin ME
Clin Genitourin Cancer; 2011 Dec; 9(2):130-2. PubMed ID: 21816687
[No Abstract] [Full Text] [Related]
12. Serum HER2 extracellular domain predicts an aggressive clinical outcome and biological PSA response in hormone-independent prostate cancer patients treated with docetaxel.
Domingo-Domenech J; Fernandez PL; Filella X; Martinez-Fernandez A; Molina R; Fernandez E; Alcaraz A; Codony J; Gascon P; Mellado B
Ann Oncol; 2008 Feb; 19(2):269-75. PubMed ID: 17998285
[TBL] [Abstract][Full Text] [Related]
13. KIFC1 induces resistance to docetaxel and is associated with survival of patients with prostate cancer.
Sekino Y; Oue N; Shigematsu Y; Ishikawa A; Sakamoto N; Sentani K; Teishima J; Matsubara A; Yasui W
Urol Oncol; 2017 Jan; 35(1):31.e13-31.e20. PubMed ID: 27665358
[TBL] [Abstract][Full Text] [Related]
14. Metastatic castrate-resistant prostate cancer with a late, complete and durable response to docetaxel chemotherapy: a case report.
Daverede L; Ralph C; Jagdev SP; Trigonis I; Trainor S; Harnden P; Weston M; Paul A; Vasudev NS
J Med Case Rep; 2014 Apr; 8():122. PubMed ID: 24717107
[TBL] [Abstract][Full Text] [Related]
15. Characterization of RNA-Binding Motif 3 (RBM3) Protein Levels and Nuclear Architecture Changes in Aggressive and Recurrent Prostate Cancer.
Carleton NM; Zhu G; Miller MC; Davis C; Kulkarni P; Veltri RW
Cancer Rep (Hoboken); 2020 Jun; 3(3):e1237. PubMed ID: 32587951
[TBL] [Abstract][Full Text] [Related]
16. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
17. Effects of Eg5 knockdown on human prostate cancer xenograft growth and chemosensitivity.
Hayashi N; Koller E; Fazli L; Gleave ME
Prostate; 2008 Sep; 68(12):1283-95. PubMed ID: 18512732
[TBL] [Abstract][Full Text] [Related]
18. Predictive and prognostic values of Tau and BubR1 protein in prostate cancer and their relationship to the Gleason score.
Cirak Y; Sarsik B; Cakar B; Sen S; Simsir A; Uslu R
Med Oncol; 2013 Jun; 30(2):526. PubMed ID: 23475578
[TBL] [Abstract][Full Text] [Related]
19. Nuclear factor-kappa B and interleukin-6 related docetaxel resistance in castration-resistant prostate cancer.
Codony-Servat J; Marín-Aguilera M; Visa L; García-Albéniz X; Pineda E; Fernández PL; Filella X; Gascón P; Mellado B
Prostate; 2013 Apr; 73(5):512-21. PubMed ID: 23038213
[TBL] [Abstract][Full Text] [Related]
20. Glucocorticoid receptor antagonism reverts docetaxel resistance in human prostate cancer.
Kroon J; Puhr M; Buijs JT; van der Horst G; Hemmer DM; Marijt KA; Hwang MS; Masood M; Grimm S; Storm G; Metselaar JM; Meijer OC; Culig Z; van der Pluijm G
Endocr Relat Cancer; 2016 Jan; 23(1):35-45. PubMed ID: 26483423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
